Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093622 · ClinicalTrials.gov registry record
Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy
A clinical trial, sponsored by Fate Therapeutics.
- Terminated
- Registry status
- 2
- Enrollment target
NCT04093622 is a clinical trial that was terminated before completion, run by Fate Therapeutics. The registered enrollment target is 2 participants.
The verdict
NCT04093622 was terminated before completion, sponsored by Fate Therapeutics.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years starting from the last administration of Fate Therapeutics genetically modified NK cell product, subjects will be assessed for long-term safety and survival through questionnaires and blood tests.
Interventions
- GENETIC Genetically engineered NK cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2020-04-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04093622
The ClinicalTrials.gov registry entry for NCT04093622 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Genetically engineered NK cells is the first listed.
NCT04093622 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04093622 about?
NCT04093622 is a clinical study titled "Long-term Follow-Up Study Following Treatment With Fate Therapeutics' Engineered Cellular Immunotherapy". The purpose of the study is to assess long-term side effects from subjects who receive a Fate Therapeutics genetically modified NK cell product. Subjects who previously took part in a Fate Therapeutics study and received genetically changed NK cells will take part in this long-term follow-up study. ...
What is the current status of trial NCT04093622?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2019-10-04. Estimated completion is 2020-04-09.
What interventions are being tested in trial NCT04093622?
The interventions under investigation include: Genetically engineered NK cells (GENETIC).
Who is sponsoring clinical trial NCT04093622?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.